Paller, A.S., Bansal, A., Simpson, E.L., Boguniewicz, M., Blauvelt, A., Siegfried, E.C., Guttman-Yassky, E., Hultsch, T., Chen, Z., Mina-Osorio, P., Lu, Y., Rossi, A.B., He, X., Kamal, M., Graham, N.M.H., Pirozzi, G., Ruddy, M., Eckert, L. and Gadkari, A. (2020) Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. American Journal of Clinical Dermatology, 21, 119-131.
https://doi.org/10.1007/s40257-019-00478-y

has been cited by the following article:

• TITLE: Punctal Stenosis a Rare Complication of Dupilumab Therapy for Atopic Dermatitis: A New Case Report

  AUTHORS: Waqas S. Abdulwahhab, Fatima Ibrahim Alamiri, Alaa S. Mehair, Fatma Abdulghaffar Qaderi

  KEYWORDS: Atopic Dermatitis, Conjunctivitis, Dupilumab, Punctual Stenosis

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.11 No.2, June 4, 2021

  ABSTRACT: Background: Dupilumab is the biological drug approved for the treatment of moderate to severe atopic dermatitis (AD) and has demonstrated impressive clinical effect and quality of life-enhancing capacity in clinical trials. The most commonly observed adverse effects of dupilumab therapy included upper respiratory tract infection, headache, nasopharyngitis, injection-site reaction, herpes viral infection, and conjunctivitis. Lacrimal duct obstruction or punctal stenosis is rarely reported side effect of dupilumab therapy and not fully documented. Aim: To document a new case presentation of a young female with a history of AD without previous significant ocular manifestations who developed right eye punctal stenosis while she was on Dupilumab therapy for a one-year duration. Case Report: A 19-year-old female with a long-standing history of AD and on dupilumab therapy for one year duration who developed severe punctal stenosis and continued tearing from her right eye in the last two months not responded to conservative ophthalmological medications but completely improved on discontinuation dupilumab injection over 6 months followed-up. Conclusions: Conjunctivitis is a well-known adverse effect of Dupilumab injection of a patient with AD. However, persistent conjunctivitis and tearing from the eye not improving on ophthalmology treatment might rule out punctal stenosis and discontinuation of dupilumab should be considered.